Cannabis and Cannabinoids on Treatment of Inflammation: A Patent Review

Menezes, Pedro Modesto Nascimento; Pereira, Emanuella Chiara Valença; Silva, Maria Eduarda Gomes da Cruz; Silva, Bismarques Augusto Oliveira da; Filho, Luiz Antonio Miranda de Souza Duarte; Araújo, Tarcísio Cícero de Lima; Lima, Kátia Simoni Bezerra; Silva, Fabrício Souza; Rolim, Larissa Araújo

doi:10.2174/1872208313666190618124345

Cited by 7 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, cannabinoids may change the balance between the response involving T-helper 1 (Th-1) and Th-2 cells, inhibiting the expression of Th-1–induced cytokines and stimulating the expression of Th-2–induced cytokines ( 53 ). More than 350 patents have been filed on cannabinoids in the treatment of inflammation ( 54 ). Ajulemic acid (anabasum), a novel selective CB2R agonist, is currently undergoing phase II and phase III clinical trials owing to its potent anti-inflammatory effect on neutrophil migration in response to ultraviolet (UV)‐killed E. coli ‐triggered dermal inflammation in humans.…”

Section: Cannabinoids In Inflammationmentioning

confidence: 99%

Cannabinoids as Key Regulators of Inflammasome Signaling: A Current Perspective

Suryavanshi

Kovalchuk

2021

Front. Immunol.

View full text Add to dashboard Cite

Inflammasomes are cytoplasmic inflammatory signaling protein complexes that detect microbial materials, sterile inflammatory insults, and certain host-derived elements. Inflammasomes, once activated, promote caspase-1–mediated maturation and secretion of pro-inflammatory cytokines, interleukin (IL)-1β and IL-18, leading to pyroptosis. Current advances in inflammasome research support their involvement in the development of chronic inflammatory disorders in contrast to their role in regulating innate immunity. Cannabis (marijuana) is a natural product obtained from the Cannabis sativa plant, and pharmacologically active ingredients of the plant are referred to as cannabinoids. Cannabinoids and cannabis extracts have recently emerged as promising novel drugs for chronic medical conditions. Growing evidence indicates the potent anti-inflammatory potential of cannabinoids, especially Δ9-tetrahydrocannabinol (Δ9-THC), cannabidiol (CBD), and synthetic cannabinoids; however, the mechanisms remain unclear. Several attempts have been made to decipher the role of cannabinoids in modulating inflammasome signaling in the etiology of chronic inflammatory diseases. In this review, we discuss recently published evidence on the effect of cannabinoids on inflammasome signaling. We also discuss the contribution of various cannabinoids in human diseases concerning inflammasome regulation. Lastly, in the milieu of coronavirus disease-2019 (COVID-19) pandemic, we confer available evidence linking inflammasome activation to the pathophysiology of COVID-19 suggesting overall, the importance of cannabinoids as possible drugs to target inflammasome activation in or to support the treatment of a variety of human disorders including COVID-19.

show abstract

Section: Cannabinoids In Inflammationmentioning

confidence: 99%

Cannabinoids as Key Regulators of Inflammasome Signaling: A Current Perspective

Suryavanshi

Kovalchuk

2021

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…In that respect, GPCR family represents a potential and innovative source of new targets. Several encouraging examples of GPCRs could play this therapeutic role in IBD through interaction with cannabinoid receptors[ 58 ], neuropeptide receptors[ 59 ], histamine receptors[ 60 ] and chemokine receptors[ 61 ]. Taking into account that OX1R was expressed in colon cancer and in precancerous lesions[ 10 ], the question is “Is OX1R expressed in IBD which represents a high risk to develop cancer?”.…”

Section: Orexins and Ibdmentioning

confidence: 99%

Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions

Couvineau¹,

Voisin²,

Nicole³

et al. 2021

WJG

View full text Add to dashboard Cite

Hypothalamic neuropeptides named hypocretin/orexins which were identified in 1998 regulate critical functions such as wakefulness in the central nervous system. These past 20 years had revealed that orexins/receptors system was also present in the peripheral nervous system where they participated to the regulation of multiple functions including blood pressure regulation, intestinal motility, hormone secretion, lipolyze and reproduction functions. Associated to these peripheral functions, it was found that orexins and their receptors were involved in various diseases such as acute/chronic inflammation, metabolic syndrome and cancers. The present review suggests that orexins or the orexin neural circuitry represent potential therapeutic targets for the treatment of multiple pathologies related to inflammation including intestinal bowel disease, multiple sclerosis and septic shock, obesity and digestive cancers.

show abstract

“…Therefore, regulating the inflammatory response is crucial for maintaining homeostasis. Inflammatory conditions are typically treated with pharmacological anti-inflammatory agents ( 3 – 6 ). However, these pharmaceuticals can cause serious complications, especially when used long term ( 7 ).…”

Section: Introductionmentioning

confidence: 99%

NF-κB-mediated anti-inflammatory effects of an organic light-emitting diode (OLED) device in lipopolysaccharide (LPS)-induced in vitro and in vivo inflammation models

Kim

Kwon

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Inflammation is the body’s physiological response to harmful agents. However, if not regulated properly, inflammation can become pathological. Macrophages are key players in the inflammatory process, and modulate the immune response. Due to the side effects of anti-inflammatory drugs, non-pharmaceutical therapies for inflammatory diseases must be developed. Photobiomodulation is a non-invasive therapeutic approach to treating certain pathological conditions using light energy. Light-emitting diodes (LEDs) are commonly used as light sources for photobiomodulation treatment, but their clinical applications are limited. Organic LEDs (OLEDs) are thin, lightweight and flexible, enabling consistent and even delivery of light energy to target areas; this makes OLED promising components for therapeutic devices. In the present study, we examined the effects of OLED treatment on inflammation in vitro using a lipopolysaccharide (LPS)-induced macrophage RAW264.7 cell model, and in vivo using a pinna skin mouse model. We found that LPS-induced morphological changes and inflammatory cytokine expression were significantly reduced in RAW264.7 cells subjected to OLED treatment compared to the LPS-induced controls. This work provides evidence for the anti-inflammatory effects of OLEDs, demonstrating their potential to be incorporated into medical devices in the future.

show abstract

Cannabis and Cannabinoids on Treatment of Inflammation: A Patent Review

Cited by 7 publications

References 31 publications

Cannabinoids as Key Regulators of Inflammasome Signaling: A Current Perspective

Cannabinoids as Key Regulators of Inflammasome Signaling: A Current Perspective

Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions

NF-κB-mediated anti-inflammatory effects of an organic light-emitting diode (OLED) device in lipopolysaccharide (LPS)-induced in vitro and in vivo inflammation models

Contact Info

Product

Resources

About